July 06, 2026 01:51 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Why can't citizens protest against the government? They are being made slaves by slapping cases': Bombay HC slams Mumbai Police, quashes activist's externment | 'First he cheats on me...': Siya Goyal's old pub video goes viral amid probe into fiancé Ketan Agarwal's alleged murder | Ronaldo's goal, Ramos' last-gasp winner send Portugal past Croatia, set up Spain clash | India-US trade deal almost done! Piyush Goyal hints at breakthrough | Ram Mandir donation scam: Champat Rai points finger at his own driver | PM Modi welcomes Japanese PM Sanae Takaichi as India-Japan ties enter a new era | 'Not an isolated incident': India slams Pakistan after 125-year-old historic Gurdwara is demolished | Ram Mandir donation theft: Six accused were employed by Varanasi-based security firm, probe reveals | Ayodhya Ram Temple donation theft: Probe says majority of money was allegedly stolen during Kumbh Mela | Commercial LPG price slashed by Rs 183.50 from July 1; check new rates in Delhi, Mumbai, Kolkata and Chennai
Sinovac
Image: Unsplash

Effectiveness of Chinese COVID-19 vaccines creating doubt

| @indiablooms | Mar 22, 2021, at 12:29 am

Effectiveness of COVID-19 vaccine prepared by China is triggering doubts across the globe.

Indonesian nurse Erny Kusuma Sukma Dewi died soon after she was given a dose of Beijing-based Sinovac Biotech's CoronaVac vaccine, reports Newsweek.

According to the National Union of Indonesian Nurses, 33-year-old Dewi contracted COVID-19 soon after she took a Chinese vaccine. Following fever, difficulty in breathing and coughing she died, reported the news magazine.

It is really surprising to many that the COVID-19 vaccine prepared by the country, which is believed to have seen the origin of the virus, has even started claiming lives.

Earlier this year, a Peruvian volunteer who took a trial of a Chinese vaccine died from COVID-19-related pneumonia. In December 2020, Peru's government suspended Sinopharm's COVID-19 vaccine because of a "serious adverse event" that occurred with a volunteer, reports Newsweek.

Brazil too reported a death due to China's Sinovac's vaccine, leading to the suspension of trials.

In January, Chinese vaccine expert Tao Lina rang an alarm on popular social networking site Weibo about Sinopharm's vaccine being the "most unsafe in the world" with 73 side effects, the news magazine reported.

Pain around the injection area, headache, high blood pressure, loss of vision, loss of taste and incontinence are among the adverse reactions outlined. As expected, Tao was silenced by Chinese authorities and his Weibo account was deleted, the magazine reported.

Countries, which are close to China, likeTurkey have been pushing hard to conduct vaccination programs using Chinese coronavirus vaccines..

However, people of the nations remain doubtful.

Sinovac dominates the supply of vaccines to Indonesia, where many are hesitant to get vaccinated due to concerns over safety and the efficacy of the jabs, according to a survey by Saiful Mujani Research and Consulting, reports Newsweek.

"Since many countries are planning to order, or have already ordered Sinovac's vaccines, it might undermine people's willingness to take them, because people may question the usefulness of the vaccines," Yanzhong Huang, a senior fellow for global health at the US based Council on Foreign Relations and expert on the Chinese health care system, told CNN.

"It could be a potential stumbling block."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.